Arsenal Biosciences to Present at the 2022 Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Arsenal Biosciences, Inc., a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, today announced that the company’s Chief Executive Officer, Ken Drazan, MD, will present in person at the 2022 Jefferies Healthcare Conference on Thursday, June 9 at 4:00 p.m. Eastern time.

2022 Jefferies Healthcare Conference
Format: Live Presentation
Date: June 9, 2022
Time: 4:00 p.m. Eastern time

The Arsenal Bio management team will also participate in one-on-one investor meetings during the conference.

About Arsenal Biosciences Inc.

Arsenal Biosciences, Inc. (ArsenalBio), located in South San Francisco, Calif., is a privately held programmable cell therapy company discovering and developing a pipeline of next-generation autologous T cell therapies to defeat cancer. Our full-stack R&D engine generates multifunctional T cell medicines, enabled by precise and specific CRISPR insertion of large synthetic DNA sequences. ArsenalBio is building the industry’s largest DNA library of therapeutic enhancing integrated circuits, incorporating logic gating for improved tumor targeting and synthetic features enabling multiple pharmaceutical functions. With our programmable and computationally driven approach and nonviral clinical manufacturing, we aim for enhanced and broader efficacy, increased patient safety, reduced stakeholder costs, and expanded market access. To learn more, visit www.arsenalbio.com and follow us on Twitter @ArsenalBio, LinkedIn and Facebook.